Hikma intros Kloxxado
Hikma is launching Kloxxado (naloxone HCl) nasal spray in a dosage strength of 8 mg.
The FDA approved the medication in April for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
Hikma noted that Kloxxado contains twice as much naloxone per spray as Narcan Nasal Spray 4 mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic.
“We are committed to ensuring Kloxxado is widely accessible to all who can benefit from it, including patients, friends, family members and the public health community,” said Brian Hoffmann, president of Hikma Generics. “As an experienced provider of addiction therapy treatments and a leading producer of nasal sprays in the United States, we are pleased to leverage our capabilities to deliver an important new tool in the fight against opioid overdose.”